Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Xinhe Xu

Dengming Xiao

Yongxin Han

Xijie Liu

Xiquan Zhang

Zhihua Liu

Yu Shen

Yong Peng

Hong Luo

Rui Zhao

Yuandong Hu

Honghao Yu

Xinlu Li

Feng Gong

Gen Li

Wei Wu

Ling Yang

Sheng Zhao

Liang Cheng

Aiming Zhang

Yinghui Sun

Fansheng Kong

Shulong Wang

Yin Wang

Jian Sun

Lipeng Zhang

Chonglong Li

Jia Tang

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition. 

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Pyridine-substituted 2-aminopyridine protein kinase inhibitors

The present invention discloses substituted 2-aminopyridine derivatives as protein kinase inhibitors; specifically, the invention relates to 2-aminopyridine derivatives having protein kinase inhibitory properties, their manufacture, pharmaceutical compositions containing them, and use of the compounds and the pharmaceutical compositions thereof for the treatment of diseases associated with protein kinase.

Substituted 2-aminopyridine protein kinase inhibitor

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

Growing community of inventors

Beijing, China

Xinhe Xu